CoChat

The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis?

Open access

The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index; 125 of the 161 sources its claims cite were checked for support.

Abstract

A strong genetic predisposition (60-80% of attributable risk) is present in Alzheimer's disease (AD). In view of this major genetic component, identification of the genetic risk factors has been a major objective in the AD field with the ultimate aim to better understand the pathological processes. In this review, we present how the genetic risk factors are involved in APP metabolism, β-amyloid peptide production, degradation, aggregation and toxicity, innate immunity, and Tau toxicity. In addition, on the basis of the new genetic landscape, resulting from the recent high-throughput genomic approaches and emerging neurobiological information, we propose an over-arching model in which the focal adhesion pathway and the related cell signalling are key elements in AD pathogenesis. The core of the focal adhesion pathway links the physiological functions of amyloid precursor protein and Tau with the pathophysiological processes they are involved in. This model includes several entry points, fitting with the different origins for the disease, and supports the notion that dysregulation of synaptic plasticity is a central node in AD. Notably, our interpretation of the latest data from genome wide association studies complements other hypotheses already developed in the AD field, i.e., amyloid cascade, cellular phase or propagation hypotheses. Genetically driven synaptic failure hypothesis will need to be further tested experimentally within the general AD framework.

Overview

CoChat Summary

TL;DR

This review synthesizes the post-GWAS genetic landscape of Alzheimer’s disease and argues that, beyond amyloid, many risk genes converge on the focal adhesion pathway and synaptic function. It proposes a “genetically driven synaptic failure” hypothesis in which APP, Tau, focal adhesion signaling, and Aβ toxicity form a circular, multi-entry model of AD pathogenesis.

Key findings

  • AD has a strong genetic predisposition, estimated at 60–80% of attributable risk; APOE alone accounts for about 20%, and more than 45 genes/loci have been associated with AD risk, while monogenic forms represent less than 1% of cases.
  • Post-GWAS genes support the amyloid cascade through APP metabolism/Aβ production (e.g., ADAM10, APH1B, BIN1, CD2AP, PICALM, ABCA7, SORL1), Aβ clearance (ApoE, CLU, PICALM, ABCA7, CR1, TREM2, CD33), and Aβ toxicity, with microglia implicated in clearance and plaque compaction.
  • Many GWAS-defined genes also modulate Tau toxicity and belong to the focal adhesion pathway (e.g., CASS4, PTK2B, EPHA1, MADD, CD2AP, FERMT2, CELF1, TLN2; BIN1 interacts with FAK/F-actin), linking APP and Tau to synaptic dynamics.
  • The authors propose an over-arching circular model in which focal adhesion/synaptic dysfunction is central, Aβ is sufficient but not necessary, and multiple entry points—APP/Tau dysfunction, Aβ toxicity, microglial dysfunction—can drive synaptic failure and cognitive decline.

Methods

  • Narrative review; no primary experimental data are reported.
  • Synthesizes AD genetics literature, including GWAS, next-generation sequencing, and post-GWAS functional studies in cellular and animal models (e.g., Drosophila, mouse, C. elegans), plus pathway and expression analyses.
  • Main analysis integrates genetic risk loci with APP/Aβ biology, Tau pathology, microglial function, focal adhesion signaling, and synapse dynamics to propose the genetically driven synaptic failure model.

Limitations

  • The authors state that GWAS-defined genes were initially characterized mainly in models built around the amyloid cascade hypothesis, creating bias, potential tautological reasoning, and a priori exclusion of other pathways; gene functions are often incompletely understood, and for some loci the responsible gene is difficult or impossible to assign due to multiple genes and complex linkage disequilibrium.
  • The authors note that a large part of AD’s genetic component remains unknown and that the proposed synaptic failure hypothesis requires further experimental testing.
  • Evident from the text: this is a review and interpretive synthesis, not a primary study; some supporting evidence is preliminary or unpublished (e.g., Kindlin-2 localization), and data linking many GWAS genes to synapses and Tau remain limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00401-019-02004-0

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Circular diagram of AD genetic risk factors. The diagram shows (from outside to inside): (1) genomic loci in alphabetical order; (2) genes therein; (3) expression profiles of these genes in different cell types of the brain (grayscale); and (4) the pathways/processes/proteins to which these genes have been functionally linked (colour). Details of the functional studies supporting these linkages are available in Suppl. Table. Expression profiles were extracted from [155] (FPKM fragments per kilobase of transcript sequence per million mapped fragments). The circlize package of the R software (http://www.r-project.org/) was used to generate the diagram [38]
Fig. 1 Circular diagram of AD genetic risk factors. The diagram shows (from outside to inside): (1) genomic loci in alphabetical order; (2) genes therein; (3) expression profiles of these genes in different cell types of the brain (grayscale); and (4) the pathways/processes/proteins to which these genes have been functionally linked (colour). Details of the functional studies supporting these linkages are available in Suppl. Table. Expression profiles were extracted from [155] (FPKM fragments per kilobase of transcript sequence per million mapped fragments). The circlize package of the R software (http://www.r-project.org/) was used to generate the diagram [38]CC BY · PubMed Central
Fig. 2 Amyloid cascade hypothesis and genetic risk factors of AD. Autosomal dominant mutations that cause early onset familial AD (in APP, PSEN1 and PSEN2) gave rise to the amyloid cascade hypothesis, which aims to link amyloid plaques and neurofibrillary tangles, the two classical AD hallmarks. Involvement of the genetic risk factors of late-onset AD in APP metabolism and in Aβ clearance through the blood brain barrier or microglia supports this hypothesis. Soluble forms of Aβ may be inducing neurotoxicity through modifying Tau metabolism, leading to neurofibrillary tangle formation and neuronal death. Recent GWAS-defined genes that modulate Tau toxicity may be involved in Aβ-induced neurotoxicity through mechanisms that are yet to be identified
Fig. 2 Amyloid cascade hypothesis and genetic risk factors of AD. Autosomal dominant mutations that cause early onset familial AD (in APP, PSEN1 and PSEN2) gave rise to the amyloid cascade hypothesis, which aims to link amyloid plaques and neurofibrillary tangles, the two classical AD hallmarks. Involvement of the genetic risk factors of late-onset AD in APP metabolism and in Aβ clearance through the blood brain barrier or microglia supports this hypothesis. Soluble forms of Aβ may be inducing neurotoxicity through modifying Tau metabolism, leading to neurofibrillary tangle formation and neuronal death. Recent GWAS-defined genes that modulate Tau toxicity may be involved in Aβ-induced neurotoxicity through mechanisms that are yet to be identifiedCC BY · PubMed Central
Fig. 3 Interactions between integrin, APP and receptor tyrosine kinases (RTKs) at the cell surface modulate cell adhesion. The GWAS-defined genes FERMT2, Cass4, PTK2B and CD2AP, recently identified for their roles in APP metabolism (in green) and/or Tau pathology (in red), are involved in the focal adhesion complex, which regulates several downstream cell signalling pathways as well as the actin cytoskeleton. This observation supports the concept that the focal adhesion core, together with its related downstream pathways, may be an important actor in the AD process
Fig. 3 Interactions between integrin, APP and receptor tyrosine kinases (RTKs) at the cell surface modulate cell adhesion. The GWAS-defined genes FERMT2, Cass4, PTK2B and CD2AP, recently identified for their roles in APP metabolism (in green) and/or Tau pathology (in red), are involved in the focal adhesion complex, which regulates several downstream cell signalling pathways as well as the actin cytoskeleton. This observation supports the concept that the focal adhesion core, together with its related downstream pathways, may be an important actor in the AD processCC BY · PubMed Central
Fig. 4 Genetic risk factors and synapse dysfunction in AD pathogenesis. Regulation of the focal adhesion pathway plays central roles in synaptic plasticity (synaptic maintenance, actin cytoskeleton remodelling, vesicle, and receptor cycling). Dysfunction of downstream cellular signalling pathways involving APP and/or Tau may thus participate in synapse loss. Additionally, dysregulation of the core FA pathway could modulate APP and Tau metabolisms, leading to an exacerbation of synaptotoxicity through Aβ overproduction and Tau-modulated excitotoxicity. Finally, Aβ availability at the synapses is dependent on its clearance through the blood brain barrier and/or by microglial cells
Fig. 4 Genetic risk factors and synapse dysfunction in AD pathogenesis. Regulation of the focal adhesion pathway plays central roles in synaptic plasticity (synaptic maintenance, actin cytoskeleton remodelling, vesicle, and receptor cycling). Dysfunction of downstream cellular signalling pathways involving APP and/or Tau may thus participate in synapse loss. Additionally, dysregulation of the core FA pathway could modulate APP and Tau metabolisms, leading to an exacerbation of synaptotoxicity through Aβ overproduction and Tau-modulated excitotoxicity. Finally, Aβ availability at the synapses is dependent on its clearance through the blood brain barrier and/or by microglial cellsCC BY · PubMed Central
Fig. 5 Reappraisal of the amyloid cascade hypothesis into a circular model. In this new model, dysfunction of the FA pathway at synapses could be the basis of a vicious cycle with multiple entry points linking AD hallmarks to synapse dysregulation, synapse loss, and subsequent cognitive decline
Fig. 5 Reappraisal of the amyloid cascade hypothesis into a circular model. In this new model, dysfunction of the FA pathway at synapses could be the basis of a vicious cycle with multiple entry points linking AD hallmarks to synapse dysregulation, synapse loss, and subsequent cognitive declineCC BY · PubMed Central

Verification

Claims the paper makes

86 Valid · 7 Not valid · 21 Not checked · 47 Own results and interpretations

100 more claims · 60 with their cited sources checked

Create a free account to see all 161 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 17
  • Not yet classified. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127. https://doi.org/10.1056/nejmoa1211851 · DOI · Paper page
  2. Jones L, Lambert J-C, Wang L-S, Choi S-H, Harold D, Vedernikov A et al (2015) Convergent genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimer’s Dement 11:658–671. https://doi.org/10.1016/j.jalz.2014.05.1757 · DOI · Paper page

Cited by

See all 168

Metadata

Authors
Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J., & Lambert, J.-C.
Affiliations
Inserm (FR)
Corresponding author
Lambert, Jean-Charles
Venue
Acta Neuropathologica
Published
2019-04-13
Volume
138
Issue
2
Pages
221-236
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2936873828
Cited by
168
References
155
Citations by year
2026: 4 · 2025: 19 · 2024: 11 · 2023: 14 · 2022: 35 · 2021: 40 · 2020: 30 · 2019: 15
FWCI
3.53
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
Funders
  • Alzheimer's Association (BFG-14-318355)
  • EU Joint Programme – Neurodegenerative Disease Research
  • Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease
  • Agence Nationale de la Recherche (ANR-11-LABX-0009, ANR-15-CE16-0002)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, genetic risk factors, amyloid hypothesis, amyloid precursor protein, amyloid-beta, tau pathology, innate immunity, focal adhesion pathway, synaptic plasticity, genome-wide association study, pathogenesis
MeSH terms
Exome Sequencing, Alzheimer Disease, Amyloid, Animals, Disease Models, Animal, Endocytosis, Humans, Models, Genetic, Models, Neurological, Neuronal Plasticity, Risk Factors, Synapses, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, tau Proteins, Genetic Predisposition to Disease, Focal Adhesions, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.